LumiThera Inc., which provides photobiomodulation treatment for ocular damage and disease, completed its acquisition of visual electrophysiology medical device manufacturer Diopsys Inc.
The acquisition will add diagnostic and monitoring capabilities to LumiThera’s existing treatment platform, the Valeda Light Delivery System, and comes before the potential release of LumiThera’s 13-month U.S. LIGHTSITE III trial data on age-related macular degeneration, LumiThera announced in a press release.
“The LIGHTSITE III trial mirrors FDA approval trials for wet AMD drugs in endpoints